» Articles » PMID: 37080423

Historical Advances in Structural and Molecular Biology and How They Impacted Vaccine Development

Overview
Journal J Mol Biol
Publisher Elsevier
Date 2023 Apr 20
PMID 37080423
Authors
Affiliations
Soon will be listed here.
Abstract

Vaccines are among the greatest tools for prevention and control of disease. They have eliminated smallpox from the planet, decreased morbidity and mortality for major infectious diseases like polio, measles, mumps, and rubella, significantly blunted the impact of the COVID-19 pandemic, and prevented viral induced cancers such as cervical cancer caused by human papillomavirus. Recent technological advances, in genomics, structural biology, and human immunology have transformed vaccine development, enabling new technologies such as mRNA vaccines to greatly accelerate development of new and improved vaccines. In this review, we briefly highlight the history of vaccine development, and provide examples of where advances in genomics and structural biology, paved the way for development of vaccines for bacterial and viral diseases.

Citing Articles

Design of Novel Vaccines Based on Virus-Like Particles.

Barcena J, Zamora-Ceballos M, Blanco E Subcell Biochem. 2024; 105:785-821.

PMID: 39738963 DOI: 10.1007/978-3-031-65187-8_21.


Structure-based design of a soluble human cytomegalovirus glycoprotein B antigen stabilized in a prefusion-like conformation.

Sponholtz M, Byrne P, Lee A, Ramamohan A, Goldsmith J, McCool R Proc Natl Acad Sci U S A. 2024; 121(37):e2404250121.

PMID: 39231203 PMC: 11406251. DOI: 10.1073/pnas.2404250121.


Viral vector- and virus-like particle-based vaccines against infectious diseases: A minireview.

Henriquez R, Munoz-Barroso I Heliyon. 2024; 10(15):e34927.

PMID: 39144987 PMC: 11320483. DOI: 10.1016/j.heliyon.2024.e34927.


The Key to Increase Immunogenicity of Next-Generation COVID-19 Vaccines Lies in the Inclusion of the SARS-CoV-2 Nucleocapsid Protein.

Mendoza-Ramirez N, Garcia-Cordero J, Shrivastava G, Cedillo-Barron L J Immunol Res. 2024; 2024:9313267.

PMID: 38939745 PMC: 11208798. DOI: 10.1155/2024/9313267.


Current Progress in Vaccines against Merkel Cell Carcinoma: A Narrative Review and Update.

Gambichler T, Schrama D, Kapynen R, Weyer-Fahlbusch S, Becker J, Susok L Vaccines (Basel). 2024; 12(5).

PMID: 38793784 PMC: 11125734. DOI: 10.3390/vaccines12050533.